Werewolf Therapeutics Inc
HOWL
NASDAQ
Biotechnology
$0.40
USD
+0.02 (+4.84%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $18.76M
Volume 274.4K
Revenue
$21.00M
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-34.61M
TTM
+52.7%
YoY
Operating Cash Flow
$-30.15M
TTM
+50.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 21.0 |
YoY Growth | -100.0% | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 21.0 |
Selling, General & Administrative | 4.4 | 4.1 | 2.5 | 5.1 | 7.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 17.5 | 15.7 | 9.4 | 13.3 | 13.8 |
Operating Income | -17.5 | -15.7 | -9.4 | -13.3 | 7.2 |
EBITDA | -17.1 | -15.3 | -9.0 | -12.9 | 9.6 |
Other Income / Expense | 0.0 | 0.0 | 1.8 | 0.7 | -3.3 |
Total Other Income / Expense | -0.4 | -0.6 | 1.0 | -0.3 | -3.5 |
Income Before Income Taxes | -18.0 | -16.4 | -8.4 | -13.5 | 3.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -18.0 | -16.4 | -8.4 | -13.5 | 3.7 |
Consolidated Net Income / Loss | -18.0 | -16.4 | -8.4 | -13.5 | 3.7 |
Net Income Attributable to Common Shareholders | -18.0 | -16.4 | -8.4 | -13.5 | 3.7 |
Basic EPS | -$0.40 | -$0.36 | -$0.17 | -$0.28 | $0.08 |
Diluted EPS | -$0.40 | -$0.36 | -$0.16 | -$0.28 | $0.08 |
Basic Shares Outstanding | 45.0M | 45.8M | 48.5M | 48.6M | 48.6M |
Diluted Shares Outstanding | 45.0M | 45.8M | 51.6M | 49.4M | 48.6M |